Latest posts
-
SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints
September 22, 2023 Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from its Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009). We are excited to share strong topline data from the Phase 1 trial of SLS009 in lymphoma patients. The
-
BioStem Technologies Initiates Nationwide Launch of AmnioWrap2™ with Venture Medical
Leading wound market solutions provider will lead BioStem’s commercialization of AmnioWrap2™ AmnioWrap2 is a versatile allograft solution for wound applications POMPANO BEACH, FLORIDA, September 19, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placenta-derived biologics for advanced wound care, has entered an agreement
-
BioStem Technologies Engages PCG Advisory for Strategic Investor Relations
POMPANO BEACH, FLORIDA, September 18, 2023 – BioStem Technologies Inc. (OTC: BSEM), an innovator in the development, manufacture, and commercialization of allografts for regenerative therapies, has engaged PCG Advisory, Inc., a leading investor relations and digital strategies firm, to serve as an advisor for investor relations and strategic communications. PCG Advisory will work closely with
-
Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier
[et_pb_section admin_label=”section”] [et_pb_row admin_label=”row”] [et_pb_column type=”4_4″][et_pb_text admin_label=”Text”] Interventional study compares VitaGraft to current transplant rejection monitoring protocols Oncocyte’s VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p<0.001) IRVINE, CA, September 18, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data
-
Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
CEO Josh Riggs will be meeting with registered investors on September 11-12, 2023 IRVINE, CA, September 6, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, at the Lotte New York Palace Hotel. Josh
-
RemSleep Holdings Inc. Announces Completion of DeltaWave CPAP Mask Testing
Tampa, FL, September 1, 2023 – RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to Obstructive Sleep Apnea (OSA) patients, provides an update on its testing protocol for 510K clearance of its DeltaWave CPAP Mask. RemSleep has completed the testing protocol for 510K clearance and
-
Bloomios Reports Q2 2023 Financial Results
Quarterly Revenue More Than Doubles to $2.7 Million Year-to-Date Revenue up 96% to $5.4 Million SANTA BARBARA, Calif., August 30, 2023 – Bloomios, Inc. (OTCQB: BLMS), a leading white-label and private-label manufacturer and wholesaler of hemp-derived nutraceutical, cosmetics and pet products, reported results for the second quarter ended June 30, 2023. All comparisons are to
-
Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage
First digital-droplet PCR assay to receive coverage Expect initial revenue generation in Q1 2024 IRVINE, CA, August 28, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a positive coverage decision for the Company’s VitaGraft
-
Oncocyte Reports Second Quarter 2023 Financial Results
Conference Call on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, August 10, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the second quarter of 2023, ended June 30, 2023. Second Quarter and Recent Highlights “In the second quarter, we made significant progress
-
ONCOCYTE REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS
IRVINE, CA, August 9, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market (“Nasdaq”) stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed. The